PTCT:NASDAQ
PTC Therapeutics, Inc.
64,91 USD
0,00%
(0,00) 1D
11-ноя., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Mkt. cap
5,42 млд
Avg. vol.
1,12 млн
Volume
1,35 миң
52-wk high
90,87 USD
52-wk low
58,80 USD
EPS
-1,38 USD
Beta
0,52
Shares outstanding
83,54 млн
No. of employees
991
Mkt. cap
5,42 млд
Avg. vol.
1,12 млн
Volume
1,35 миң
52-wk high
90,87 USD
52-wk low
58,80 USD
EPS
-1,38 USD
Beta
0,52
Shares outstanding
83,54 млн
No. of employees
991
News stories
From web sources and news partners
Yahoo Finance
·
32 мүнөт мурун
Stock market today: S&P 500, Nasdaq futures sink as Nvidia CEO turmoil jolts confidence
CNBC
·
32 мүнөт мурун
Stock futures decline as Nvidia shares fall, Trump says no deal needed with Iran: Live updates
Investopedia
·
16 саат мурун
Markets News, Nov. 11, 2026: S&P 500, Nasdaq Surge as CoreWeave Paces Big AI Rally; Chip Stocks Jump as Nvidia Rebounds
Reuters
·
1 саат мурун
Nasdaq, S&P 500 futures fall as Nvidia turbulence unsettles AI stocks
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded1998-ж., 1-янв.
HeadquartersУоррен, Нью Джерси, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websiteptcbio.com